Hospital
Westfield Memorial Hospital, INC.
Westfield Memorial Hospital, INC. was paid $2.71M by Medicaid between Jan 2018 and Nov 2024, across 74 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoWESTFIELD MEMORIAL HOSPITAL, INC.
WESTFIELD, NY 14787
WESTFIELD, NY 14787
33aNPI1942236427assigned 06/24/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.71M
24GClaims58,580
24DCodes billed74
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#104 of 231
Median peer was paid$561K
This provider vs. median4.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 497 | $11K | |
| 2019 | 3,846 | $141K | |
| 2020 | 7,597 | $353K | |
| 2021 | 11,627 | $529K | |
| 2022 | 11,789 | $517K | |
| 2023 | 14,615 | $738K | |
| 2024incomplete | 8,609 | $422K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 5,849 | 5,620 | $796K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 2,899 | 2,773 | $616K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 3,102 | 2,969 | $556K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 716 | 694 | $128K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.3% | 1,098 | 1,081 | $117K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.9% | 713 | 672 | $105K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 375 | 363 | $66K |
| 80053 | Comprehensive metabolic panel | 2.1% | 3,659 | 3,323 | $57K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 1,390 | 387 | $56K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.9% | 882 | 881 | $52K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 396 | 353 | $37K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 312 | 307 | $21K |
62 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,274 | $18K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 80 | $17K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 111 | $17K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 239 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,867 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 627 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,018 | $5K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 14 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,792 | $2K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,412 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,978 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 85 | $2K |
| 97162 | <1% | 16 | $2K | |
| 97163 | <1% | 17 | $1K | |
| 81025 | <1% | 646 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,382 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 155 | $1K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 13 | $1K |
| 81001 | <1% | 2,767 | $932.94 | |
| 84484 | <1% | 1,473 | $845.47 | |
| 83690 | <1% | 1,632 | $670.98 | |
| 83735 | <1% | 1,155 | $637.51 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,383 | $578.86 |
| 36415 | Collection of venous blood by venipuncture | <1% | 544 | $549.27 |
| 90715 | <1% | 17 | $479.79 | |
| 83605 | <1% | 324 | $479.34 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $459.13 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 540 | $425.10 |
| 73630 | <1% | 90 | $354.37 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,238 | $337.76 |
| 76642 | <1% | 13 | $336.03 | |
| 80076 | <1% | 40 | $329.41 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 149 | $308.92 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 986 | $267.76 |
| 71045 | Radiologic examination, chest; single view | <1% | 311 | $249.01 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 37 | $217.77 |
| 87088 | <1% | 253 | $190.92 | |
| 85379 | <1% | 104 | $157.42 | |
| 72100 | <1% | 14 | $94.48 | |
| 73610 | <1% | 36 | $70.68 | |
| 80061 | Lipid panel | <1% | 12 | $62.43 |
| 84703 | <1% | 539 | $58.99 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 959 | $49.45 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 17 | $45.00 |
| 73030 | <1% | 12 | $41.35 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 30 | $41.25 |
| 87040 | <1% | 102 | $40.75 | |
| 87077 | <1% | 39 | $25.55 | |
| 85730 | <1% | 13 | $18.57 | |
| 73130 | <1% | 12 | $15.16 | |
| 73110 | <1% | 12 | $15.16 | |
| 85610 | <1% | 13 | $11.73 | |
| 81003 | <1% | 77 | $10.10 | |
| 87807 | <1% | 41 | $5.70 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 44 | $3.07 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 12 | $2.24 |
| A9270 | Non-covered item or service | <1% | 3,880 | $1.83 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 17 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 12 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 478 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 12 | $0.00 |
| 87186 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSURKALA, KAREN (PRESIDENT)